Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha-Mei Liao

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in VivoEdwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Plos One|October 25, 2014
Lack of involvement of CEP adducts in TLR activation and in angiogenesisJohn Gounarides, Jennifer S Cobb, Jing Zhou, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
Journal of Medicinal Chemistry|April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement PathwayRajeshri G Karki, James Powers, Nello Mainolfi, et al.
Nature Communications|June 13, 2022
A proteogenomic signature of age-related macular degeneration in bloodValur Emilsson, Elias F Gudmundsson, Thorarinn Jonmundsson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2019
Small-molecule factor B inhibitor for the treatment of complement-mediated diseasesAnna Schubart, Karen Anderson, Nello Mainolfi, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in VivoEdwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Plos One|October 25, 2014
Lack of involvement of CEP adducts in TLR activation and in angiogenesisJohn Gounarides, Jennifer S Cobb, Jing Zhou, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
Journal of Medicinal Chemistry|April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement PathwayRajeshri G Karki, James Powers, Nello Mainolfi, et al.
Nature Communications|June 13, 2022
A proteogenomic signature of age-related macular degeneration in bloodValur Emilsson, Elias F Gudmundsson, Thorarinn Jonmundsson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2019
Small-molecule factor B inhibitor for the treatment of complement-mediated diseasesAnna Schubart, Karen Anderson, Nello Mainolfi, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 2